CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 7, 2026 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Identification No.) 7 Times Square, Suite 2503 New York, ...

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) saw unusually large options trading on Friday. Traders bought 149,934 call options on the company. This is an increase of approximately 829% compared to the average volume of 16,138 call options. Get SELLAS Life Sciences Group alerts: Analyst Upgrades and DowngradesSeparately, Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, October 8th. One equities research analyst has rate ...

Shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) fell sharply during Friday's session after the company announced plans to raise fresh capital.Intelligent Bio said it will raise $10 million through a private placement, which weighed on shares following the announcement.Intelligent Bio Solutions shares dipped 19.7% to $7.65 on Friday.Here are some other stocks moving in today’s mid-day session.GainersLavoro Limited (NASDAQ:LVRO) jumped 181% to $1.2900.Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) rose 5 ...

Core Viewpoint - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Group 1: Premarket Gainers - SMX (Security Matters) Public Limited Company (SMX) is up 39% at $22.80 [3] - Rubico Inc. (RUBI) has increased by 21% to $1.30 [3] - Aimei Health Technology Co., Ltd (AFJK) is up 19% at $76.80 [3] - Sable Offshore Corp. (SOC) has risen 19% to $10.81 [3] - Diginex Limited (DGNX) is up 18% at $4.95 [3] - Sidus Space, Inc. (SIDU) has increased by 18% to $3.71 [3] - SELLAS Life Sciences Group, Inc. (SLS) is up 16% at $4.40 [3] - Alchemy Investments Acquisition Corp 1 (ALCY) has risen 14% to $16.24 [3] - Greenidge Generation Holdings Inc. (GREE) is up 11% at $1.65 [3] - Enigmatig Limited (EGG) has increased by 5% to $5.52 [3] Group 2: Premarket Losers - Intelligent Bio Solutions Inc. (INBS) is down 11% at $8.48 [4] - ZW Data Action Technologies Inc. (CNET) has decreased by 11% to $1.20 [4] - Nuvve Holding Corp. (NVVE) is down 9% at $2.31 [4] - ESH Acquisition Corp. (ESHA) has fallen 8% to $17.59 [4] - LZ Technology Holdings Limited (LZMH) is down 6% at $1.55 [4] - Oriental Rise Holdings Limited (ORIS) has decreased by 4% to $1.43 [4] - Cango Inc. (CANG) is down 3% at $1.45 [4] - Massimo Group (MAMO) has fallen 2% to $3.90 [4] - Anghami Inc. (ANGH) is down 2% at $3.68 [4] - AIM ImmunoTech Inc. (AIM) has decreased by 2% to $1.10 [4]

Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and strategic buyouts.-- ARS Pharma's neffy, an emergency treatment for allergic reactions, received regulatory approval in China, while Vanda's NEREUS secured in the United States. -- FONAR Corp., the inventor of MR Scanning, is set to be taken private by its CEO-LED group. -- New analyses from InflaRx's halted phase 3 Vilobelimab trial h ...

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday.Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) rose sharply during Wednesday's session after the company announced it intends to file a new drug application in January for AXS-12 after receiving feedback from the FDA. Additionally, the company announced the FDA granted Priority Review to AXS-05 for Alzheimer’s Agitation.Axsome Therapeutics shares surged 16.1% to $172.90 on Wednesday.Here are some other big stocks r ...

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.Shares of Mereo BioPharma Group plc – ADR (NASDAQ:MREO) fell sharply in pre-market trading after the company announced its Phase 3 ORBIT and COSMIC Studies for setrusumab in Osteogenesis Imperfecta did not achieved statistical significance against the primary endpoints of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates, respectively.Mereo BioPharma Group shares tumbled 8 ...

Core Viewpoint - SELLAS Life Sciences Group, Inc. is advancing its Phase 3 REGAL trial for GPS as a potential maintenance therapy in patients with acute myeloid leukemia (AML) after second complete remission, with the trial currently reporting 72 events as of December 26, 2025, and awaiting the 80 events needed for final analysis [1][3][7] Group 1: Trial Update - The Independent Data Monitoring Committee (IDMC) recommended that the Phase 3 REGAL trial continue without modification, with expectations that the required 80 events (deaths) for final analysis would occur before year-end [2] - As of December 26, 2025, the trial has recorded 72 events, and SELLAS remains blinded to all efficacy and survival data outcomes, meaning this update does not affect future statistical analyses [3][7] - The final analysis is event-driven, and the company will announce when the 80th event occurs [3][7] Group 2: Company Commitment and Expert Insights - The CEO of SELLAS expressed appreciation for the dedication of participants in the REGAL trial, noting that survival times appear longer than expected, which may increase the probability of a successful study [4] - Dr. Yair Levy, a member of the REGAL Steering Committee, highlighted the significance of the REGAL study in evaluating GPS for AML patients who cannot undergo transplant, with an expected median overall survival of around eight months for current treatments [4] - The company is committed to advancing breakthrough therapies like GPS that have the potential to significantly improve patient outcomes in AML [4] Group 3: About the REGAL Trial - The REGAL trial (NCT04229979) is a Phase 3 randomized registrational clinical trial for GPS in AML patients who have achieved complete remission following second-line salvage therapy [5] - The primary endpoint of the trial is overall survival, and the IDMC is responsible for monitoring patient safety and efficacy data [5] Group 4: About SELLAS Life Sciences - SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for various cancer indications, with its lead product candidate GPS targeting the WT1 protein present in multiple tumor types [6] - The company is also developing SLS009, a differentiated small molecule CDK9 inhibitor, which has shown a high response rate in AML patients with unfavorable prognostic factors [8]

Core Insights - SELLAS Life Sciences Group, Inc. announced promising clinical data for SLS009, a CDK9 inhibitor, in combination with azacitidine and venetoclax for treating relapsed or refractory acute myeloid leukemia with myelodysplastic syndrome-related changes [1][3] Group 1: Clinical Study Details - The Phase 2 study involved 35 evaluable patients with a median age of 69, where 98% had ELN adverse-risk AML, with common mutations including ASXL1, RUNX1, TP53, and SRSF2 [2] - The overall response rate for SLS009 in combination with AZA/VEN was 46%, with 29% achieving complete response (CR) or CR with incomplete blood count recovery (CRi) [3] - Patients with ASXL1 and TP53 mutations had response rates of 48% and 57%, respectively, with median overall survival (mOS) significantly exceeding the expected 2.6 months [3] Group 2: Safety and Tolerability - No dose-limiting toxicities (DLTs) or treatment-related deaths were reported, indicating that the combination therapy was well tolerated [3][5] - The combination therapy demonstrated a median overall survival of 8.9 months in the least pretreated cohort, with a 58% response rate in patients with one prior line of therapy [5] Group 3: Future Plans and Implications - The company plans to expand the study to evaluate SLS009 plus AZA/VEN in newly diagnosed AML with high-risk features in Q1 2026 [5] - The results suggest that SLS009 may effectively overcome resistance to venetoclax-based regimens by targeting MCL-1, a key resistance mechanism in AML [4]

Core Insights - Several small-cap healthcare and biotech companies experienced significant price increases in after-hours trading following earnings updates or upcoming financial disclosures [1] Company Summaries - MacroGenics, Inc. (MGNX) saw a 10.2% rise to $1.62 after hours, recovering from a 3.29% decline during the regular session. The company reported a third-quarter net income of $16.8 million, or $0.27 per share, down from $56.3 million, or $0.90 per share, year-over-year. Revenue fell to $72.8 million from $110.7 million [2] - SELLAS Life Sciences Group, Inc. (SLS) advanced 9.4% to $1.63 in after-hours trading. The company narrowed its quarterly net loss to $6.8 million, or $0.06 per share, compared to $7.1 million, or $0.10 per share, in the prior-year quarter. As of September 30, 2025, SELLAS reported cash and equivalents of approximately $44.3 million [3] - Standard BioTools Inc. (LAB) increased by 4.24% to $1.23 after hours, despite no official press releases or updates on Wednesday. The stock had closed slightly lower during the regular session [4] - KORU Medical Systems, Inc. (KRMD) gained 8.47% to $4.10 after hours, following a 1.34% increase earlier in the day. The company reported a narrower net loss of $0.8 million for the third quarter, compared to $1.6 million in the prior-year period. Revenue rose 27.2% to $10.4 million. KORU also raised its full-year revenue guidance to a range of $40.5 million - $41.0 million and reaffirmed its gross margin outlook of 61%-63% [5] - Hyperfine, Inc. (HYPR) climbed 8.18% to $1.19 after hours. No new announcements were made on Wednesday, but the company is scheduled to release its third-quarter results on Thursday, with analysts anticipating a loss of $0.10 per share and revenue of $3.52 million [6] - Wave Life Sciences Ltd. (WVE) added 5.68% to reach $7.35 in after-hours trading. The company reported a third-quarter net loss of $53.9 million, an improvement from $61.8 million in the prior-year quarter. Revenue for the period was $7.6 million, compared to a negative revenue figure of ($7.7) million last year [7]